percentage of cores with grade group 2-5 at systematic biopsy was associated with ECE (P<0.01) and SVI (P<0.01). At DCA, models including mpMRI data and accounting for cores obtained from MRItargeted and from systematic biopsy yield the highest net benefit compared to the other tools. A 40% cut-off to predict ECE of the novel model was associated with a higher sensitivity compared to the same cut-off of the model based on clinical parameters and mpMRI only (78 vs 73%). A 15% cut-off of the SVI risk tool was associated with a higher sensitivity (74 vs 68%).
INTRODUCTION AND OBJECTIVES:
Various recent literature suggests that a negative multiparametric MRI (mpMRI) allows to rule out significant prostate cancer. The objective of our study was to investigate whether a specific portion of D'Amico intermediate risk group could be reclassified as low risk if the mpMRI is negative. We evaluated the histopathological results after radical prostatectomy (RP) in preoperative D'Amico intermediate risk patients that had a negative preoperative mpMRI.
METHODS: We retrospectively identified 604 D'Amico intermediate risk patients and 355 low risk patients among 1,347 who underwent a preoperative mpMRI and radical prostatectomy in a single institution. Intermediate risk patients were sub-classified according to Gleason score, clinical stage and preoperative PSA level and the positivity of mpMRI. The final pathology from each RP specimen of each sub-classified group was compared with that of D'Amico low risk group. The MRIs were considered negative when no suspicious lesion was seen or when PI-RAD Version 2 grade 2. Patients with advanced pathologic stage (pT3-T4 and/or pN1) and/or a pGS 4 þ 3 were considered as "unfavorable disease" at RP. Pathologic stage pT3-4 or pN1 was classified as "non-organ-confined disease". RESULTS: Among 604 intermediate risk group patients, 48 patients were PSA only elevated group (Gleason 6, cT1-cT2b and PSA 10 to 20 ng/dl) with negative MRI. The rate of unfavorable disease was 18.8% (9/48) and non-organ confined disease was 10.4% (5/48) among the subgroup. Pathological profile of this subgroup was comparable with D'Amico low risk group in terms of the risk of unfavorable disease and non-organ-confined disease. The comparability was still consistent even after 1:4 propensity score matching of clinical profiles exceptliterature preoperative PSA (Table) . The rate of unfavorable disease or nonorgan-confined disease among other subgroups were significantly worse than D'Amico low risk group regardless the findings of mpMRI.
CONCLUSIONS: In case of negative mpMRI, If the only violation of D'Amico low risk criterion is moderate PSA elevation ( 20ng/ml), the pathological outcome was comparable with conventional literature group. Our results suggest that the oncological hazard of such specific portion of conventional D'Amico intermediate risk group could be considered as low risk in the era of mpMRI.
Source of Funding: None

MP09-04 DOES TUMOR CONTACT LENGTH ON MRI REFLECT EXTRACAPSULAR EXTENSION AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY?
Sho Uehara*, Yoh Matsuoka, Hiroshi Tanaka, Yosuke Yasuda, Shingo Moriyama, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Kazutaka Saito, Yasuhisa Fujii, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Tumor contact length (TCL), defined as the length of a lesion in contact with the prostatic capsule on MRI, is an objective marker. TCL >10 mm was added to the extracapsular extension (ECE) criteria of PI-RADS version 2; however, we have reported these criteria could increase overstaging (AJR 2017). Additionally, the impact of TCL on biochemical recurrence (BCR) after radical prostatectomy (RP) has not been established. Several studies reported that the extent of pathological ECE (pECE) is associated with BCR after RP. The aim of this study is to investigate the impact of TCL on the extent of pECE and BCR after RP.
METHODS: We enrolled 220 clinically localized prostate cancer patients who had undergone MRI and RP without prior treatment. MRI findings including PI-RADS score, tumor diameter (TD), morphologic features suggestive of ECE (MF-ECE), and TCL were assessed. BCR was defined as PSA >0.2 ng/ml. Preoperative variables including MRI findings were examined for association with pECE and BCR by logistic and Cox regression analyses, respectively. To evaluate the extent of pECE, the radial length was measured based on a previous report (Am J Surg Pathol 2007). We defined pECE with a radial length of >0.6 mm as extensive ECE.
RESULTS: Median PSA was 6.8 ng/ml. PI-RADS scores 2/3/ 4/5 were found in 18/30/75/97 men (8/14/34/44%), and MF-ECE was identified in 73 men (33%). Median TD and TCL were 13 mm and 10 mm, respectively. Biopsy ISUP grade group (bGG) 1/2/3/!4 were found in 43/69/17/6 men. Fifty-six men (25%) had pECE, 24 men (11%) had extensive ECE, and 61 men (28%) experienced BCR at a median follow-up of 49 months. Multivariate analysis showed MF-ECE (odds ratio [OR] 4.7, p <0.001) and TCL >10 mm (OR 7.6, p [ 0.002) were independent predictors for pECE. However, multivariate analysis for extensive ECE showed MF-ECE (OR 9.9, p <0.001) was a single independent predictor, while TCL >10 mm was not. Regarding BCR, PSA (hazard ratio [HR] 1.05, p [ 0.01), bGG (HR 1.8, p <0.001), and MF-ECE (HR 2.8, p <0.001) were independent predictors, whereas TCL >10 mm was not. Extensive ECE was identified in 2 of 44 men with TCL >10 mm and without MF-ECE and in 17 of 60 men with TCL >10 mm and with MF-ECE, respectively (5% vs. 28%, p [ 0.002).
CONCLUSIONS: TCL >10 mm is useful in the detection of pECE. However, TCL alone does not have a significant impact on the prediction of extensive ECE and BCR after RP.
Source of Funding: none
MP09-05 CLINICAL, PATHOLOGIC, AND ONCOLOGIC FINDINGS OF RADICAL PROSTATECTOMY PATIENTS WITH EXTRAPROSTATIC EXTENSION DIAGNOSED ON PRE-OPERATIVE PROSTATE BIOPSY
Farzana Faisal*, Baltimore, MD; Jeffrey Tosoian, Ann Arbor, MI; Misop Han, Katarzyna Macura, Christian Pavlovich, Tamara Lotan, Baltimore, MD INTRODUCTION AND OBJECTIVES: Prostatic adenocarcinoma (PCa) with extraprostatic extension (EPE) detected on prostate needle biopsy (PNB) is an uncommon finding, and its clinical implications are limited. We aimed to describe the clinical and pathologic findings in a large cohort of PCa patients treated with radical prostatectomy (RP) who had EPE identified on PNB.
METHODS: Using our institutional pathology database, we identified 83 PCa cases with EPE on PNB between 2000-2018 who
